Status:
COMPLETED
TACE for HCC by TANDEM and Idarubicin
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
18+ years
Brief Summary
DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al...
Eligibility Criteria
Inclusion
- HCC according to histological examination or Barcelona criteria Measurable targets according to mRECIST v1.1 Child A or B7 cirrhosis (without decompensation in the past 6 months) HCC not candidate to surgery or ablation Age ≥ 18 years Performance status 0 or 1 Thrombocytes ≥ 50 000/mm3, neutrophil count≥ 1 000/mm3, creatininemia ≤ 150 µmol/L No cardiac failure
Exclusion
- Follow-up \< 1month Lobar/main portal venous thrombus Prior treatment by systemic chemotherapy or radioembolization
Key Trial Info
Start Date :
December 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2018
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT03349957
Start Date
December 1 2017
End Date
March 30 2018
Last Update
April 25 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295